Delhi Journal of Ophthalmology

All About Prostaglandin Analogues in Eye

Priti Kumari, Madhu Bhoot
Glaucoma Department, Dr. Shroff’s Charity Eye Hosptial, Daryaganj, New Delhi, India

Editor-in-Chief, Delhi Journal of Ophthalmology, Dr R.P.Centre, AIIMS.

Corresponding Author:

Madhu Bhoot (DNB)
Dr. Shroff’s Charity Eye Hospital, 
5027, Kedar Nath Road, Daryaganj, 
New Delhi - 100002, India
Email id:

Received: 25-JUL-2019 Accepted: 28-NOV-2019 Published Online: 09-MAY-2020

Glaucoma is a leading cause of impairment of vision worldwide. Raised intraocular pressure can cause damage to both optic nerve and retinal ganglion cells. Reducing intraocular pressure is the only modifiable risk factor for this disease available presently. It can be achieved either by surgical or medical treatment. Pharmacotherapy is the mainstay of treatment for glaucoma patients. Prostaglandins analogues have replaced beta blockers as the first line anti-glaucoma drug. Their single dose per day, better diurnal control of IOP and long washout period has ensured better compliance and better results in various forms of glaucoma. A lot of clinical research is ongoing in developing new prostaglandin derivatives with safer profiles and more targeted action. This article will be reviewing the various merits and demerits of prostaglandin analogues in practice as well as shed some light on the newer drugs in pipeline.

Keywords :Glaucoma, Prostaglandins, anti-glaucoma drugs

Search PubMed for

Search Google Scholar for

Article Statistics